论文部分内容阅读
目的:探讨分化抑制因子nm23-H1蛋白在急性白血病患儿血浆中的表达水平与预后的关系。方法:采用酶联免疫法测定分化抑制因子nm23-H1蛋白在80例初治急性白血病(AL)患儿及6例复发的AL患儿、14例持续完全缓解的AL患儿和30例健康志愿者血浆中的含量。结果:nm23-H1在初治及复发的AL患儿中明显高于健康志愿者,持续完全缓解的AL患儿nm23-H1血浆浓度与健康志愿者血浆中的含量无显著差异。耐药组nm23-H1血浆浓度明显高于非耐药组。结论:nm23-H1蛋白在急性白血病患儿血浆中不同病期表达水平不同,高表达者预后差。提示nm23-H1血浆蛋白浓度可能是判断急性白血病患儿预后的一种标志。
Objective: To investigate the relationship between the expression of nm23-H1 protein and the prognosis in children with acute leukemia. Methods: Enzyme-linked immunosorbent assay was used to determine the expression of nm23-H1 protein in 80 newly diagnosed AL children and 6 AL children with relapsed AL. 14 AL patients with complete remission and 30 healthy volunteers Plasma content. Results: nm23-H1 was significantly higher in healthy and newly diagnosed relapsed AL children than in healthy volunteers. There was no significant difference in the plasma concentrations of nm23-H1 between healthy and non-relapsed AL children. The drug-resistant group nm23-H1 plasma concentrations were significantly higher than non-drug-resistant group. Conclusion: The expression of nm23-H1 protein in plasma of children with acute leukemia at different stages is different, with high expression of poor prognosis. Tip nm23-H1 plasma protein concentration may be to determine the prognosis of children with acute leukemia a sign.